STOCK TITAN

[8-K] Sensei Biotherapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Viatris Inc. (NASDAQ: VTRS) filed an 8-K announcing a governance change. On 4 Aug 2025 the Board expanded from 14 to 15 seats and appointed David Simmons as an independent director, effective immediately. His initial term runs until the 2025 annual meeting of shareholders. The Board has not yet assigned him to any committees; an amended 8-K will be filed once those committee appointments are finalized.

Mr. Simmons will receive the standard cash and equity compensation provided to Viatris’ other non-employee directors, and the Company has executed its customary indemnification agreement with him (form previously filed as Exhibit 10.25 to the 2020 Form 10-K). Management states that there are no arrangements or related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.

A press release dated 5 Aug 2025 announcing the appointment is furnished as Exhibit 99.1 under Item 7.01 and is expressly deemed not filed for liability purposes. No financial statements accompany this report.

Viatris Inc. (NASDAQ: VTRS) ha presentato un modulo 8-K annunciando un cambiamento nella governance. Il 4 agosto 2025 il Consiglio di Amministrazione è passato da 14 a 15 membri e ha nominato David Simmons come amministratore indipendente, con effetto immediato. Il suo mandato iniziale durerà fino all'assemblea annuale degli azionisti del 2025. Il Consiglio non lo ha ancora assegnato a nessun comitato; un modulo 8-K modificato sarà presentato non appena saranno finalizzate queste nomine.

Il signor Simmons riceverà la consueta remunerazione in denaro e azioni prevista per gli altri amministratori non dipendenti di Viatris, e la Società ha stipulato con lui il consueto accordo di indennizzo (modulo precedentemente presentato come Allegato 10.25 al Modulo 10-K del 2020). La direzione dichiara che non esistono accordi o transazioni con parti correlate da divulgare ai sensi dell'Elemento 404(a) del Regolamento S-K.

Un comunicato stampa datato 5 agosto 2025 che annuncia la nomina è fornito come Allegato 99.1 nell'Elemento 7.01 ed è espressamente considerato non presentato ai fini di responsabilità legale. Nessun bilancio accompagna questo rapporto.

Viatris Inc. (NASDAQ: VTRS) presentó un formulario 8-K anunciando un cambio en la gobernanza. El 4 de agosto de 2025, la Junta aumentó de 14 a 15 miembros y nombró a David Simmons como director independiente, con efecto inmediato. Su mandato inicial se extiende hasta la reunión anual de accionistas de 2025. La Junta aún no lo ha asignado a ningún comité; se presentará un 8-K enmendado una vez que se finalicen esos nombramientos.

El Sr. Simmons recibirá la compensación estándar en efectivo y acciones que se otorga a los demás directores no empleados de Viatris, y la Compañía ha ejecutado el acuerdo habitual de indemnización con él (formulario presentado previamente como Anexo 10.25 al Formulario 10-K de 2020). La administración declara que no existen acuerdos ni transacciones con partes relacionadas que deban divulgarse bajo el Ítem 404(a) del Reglamento S-K.

Un comunicado de prensa fechado el 5 de agosto de 2025 que anuncia el nombramiento se presenta como Anexo 99.1 bajo el Ítem 7.01 y se considera expresamente no presentado para fines de responsabilidad. No se adjuntan estados financieros a este informe.

Viatris Inc. (NASDAQ: VTRS)는 거버넌스 변경을 알리는 8-K 보고서를 제출했습니다. 2025년 8월 4일 이사회는 14명에서 15명으로 확대되었으며, David Simmons를 독립 이사로 즉시 임명했습니다. 그의 초기 임기는 2025년 연례 주주총회까지입니다. 이사회는 아직 그를 어떤 위원회에도 배정하지 않았으며, 위원회 배정이 완료되는 대로 수정된 8-K 보고서를 제출할 예정입니다.

Simmons 씨는 Viatris의 다른 비직원 이사들에게 제공되는 표준 현금 및 주식 보상을 받으며, 회사는 그와 관례적인 면책 계약(2020년 10-K 보고서의 부속서 10.25로 이전 제출된 양식)을 체결했습니다. 경영진은 규정 S-K의 항목 404(a)에 따라 공개가 필요한 관련 당사자 거래나 합의가 없다고 밝혔습니다.

2025년 8월 5일자 임명 발표 보도자료는 항목 7.01 아래 부속서 99.1로 제공되며, 법적 책임 목적상 제출된 것으로 간주되지 않습니다. 이 보고서에는 재무제표가 첨부되어 있지 않습니다.

Viatris Inc. (NASDAQ : VTRS) a déposé un formulaire 8-K annonçant un changement de gouvernance. Le 4 août 2025, le conseil d'administration est passé de 14 à 15 membres et a nommé David Simmons en tant qu'administrateur indépendant, avec effet immédiat. Son mandat initial court jusqu'à l'assemblée générale annuelle des actionnaires de 2025. Le conseil ne l'a pas encore affecté à des comités ; un formulaire 8-K modifié sera déposé une fois ces nominations finalisées.

M. Simmons recevra la rémunération habituelle en espèces et en actions versée aux autres administrateurs non salariés de Viatris, et la société a conclu avec lui son accord d'indemnisation habituel (formulaire précédemment déposé en annexe 10.25 au formulaire 10-K de 2020). La direction déclare qu'il n'existe aucun accord ou transaction avec des parties liées nécessitant une divulgation selon l'Item 404(a) du règlement S-K.

Un communiqué de presse daté du 5 août 2025 annonçant la nomination est fourni en tant que Pièce 99.1 sous l'Item 7.01 et est expressément considéré comme non déposé aux fins de responsabilité. Aucun état financier n'accompagne ce rapport.

Viatris Inc. (NASDAQ: VTRS) hat ein 8-K Formular eingereicht, das eine Änderung in der Unternehmensführung ankündigt. Am 4. August 2025 wurde der Vorstand von 14 auf 15 Mitglieder erweitert und David Simmons als unabhängiges Vorstandsmitglied mit sofortiger Wirkung ernannt. Seine erste Amtszeit läuft bis zur Hauptversammlung 2025. Der Vorstand hat ihn noch keinen Ausschüssen zugewiesen; ein geändertes 8-K wird eingereicht, sobald diese Ausschusszuweisungen abgeschlossen sind.

Herr Simmons erhält die übliche Bar- und Aktienvergütung, die auch den anderen nicht angestellten Direktoren von Viatris gewährt wird, und das Unternehmen hat mit ihm die übliche Entschädigungsvereinbarung abgeschlossen (Formular zuvor als Anlage 10.25 zum 2020er 10-K eingereicht). Das Management erklärt, dass keine Vereinbarungen oder Transaktionen mit nahestehenden Personen vorliegen, die gemäß Punkt 404(a) der Regulation S-K offenzulegen wären.

Eine Pressemitteilung vom 5. August 2025, die die Ernennung ankündigt, wird als Anlage 99.1 unter Punkt 7.01 bereitgestellt und gilt ausdrücklich nicht als eingereicht im Hinblick auf Haftungszwecke. Dem Bericht sind keine Finanzberichte beigefügt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 8-K adds an independent director; negligible immediate financial impact.

The filing is straightforward governance disclosure. Expanding the board and adding an independent director aligns with best-practice standards and may marginally enhance oversight, but investors should not expect near-term earnings or valuation effects. Committee assignments and Mr. Simmons’ industry experience—details not provided here—will determine longer-term influence. No related-party concerns are noted, and compensation mirrors other non-employee directors. Overall, the event is neutral for the investment thesis.

Viatris Inc. (NASDAQ: VTRS) ha presentato un modulo 8-K annunciando un cambiamento nella governance. Il 4 agosto 2025 il Consiglio di Amministrazione è passato da 14 a 15 membri e ha nominato David Simmons come amministratore indipendente, con effetto immediato. Il suo mandato iniziale durerà fino all'assemblea annuale degli azionisti del 2025. Il Consiglio non lo ha ancora assegnato a nessun comitato; un modulo 8-K modificato sarà presentato non appena saranno finalizzate queste nomine.

Il signor Simmons riceverà la consueta remunerazione in denaro e azioni prevista per gli altri amministratori non dipendenti di Viatris, e la Società ha stipulato con lui il consueto accordo di indennizzo (modulo precedentemente presentato come Allegato 10.25 al Modulo 10-K del 2020). La direzione dichiara che non esistono accordi o transazioni con parti correlate da divulgare ai sensi dell'Elemento 404(a) del Regolamento S-K.

Un comunicato stampa datato 5 agosto 2025 che annuncia la nomina è fornito come Allegato 99.1 nell'Elemento 7.01 ed è espressamente considerato non presentato ai fini di responsabilità legale. Nessun bilancio accompagna questo rapporto.

Viatris Inc. (NASDAQ: VTRS) presentó un formulario 8-K anunciando un cambio en la gobernanza. El 4 de agosto de 2025, la Junta aumentó de 14 a 15 miembros y nombró a David Simmons como director independiente, con efecto inmediato. Su mandato inicial se extiende hasta la reunión anual de accionistas de 2025. La Junta aún no lo ha asignado a ningún comité; se presentará un 8-K enmendado una vez que se finalicen esos nombramientos.

El Sr. Simmons recibirá la compensación estándar en efectivo y acciones que se otorga a los demás directores no empleados de Viatris, y la Compañía ha ejecutado el acuerdo habitual de indemnización con él (formulario presentado previamente como Anexo 10.25 al Formulario 10-K de 2020). La administración declara que no existen acuerdos ni transacciones con partes relacionadas que deban divulgarse bajo el Ítem 404(a) del Reglamento S-K.

Un comunicado de prensa fechado el 5 de agosto de 2025 que anuncia el nombramiento se presenta como Anexo 99.1 bajo el Ítem 7.01 y se considera expresamente no presentado para fines de responsabilidad. No se adjuntan estados financieros a este informe.

Viatris Inc. (NASDAQ: VTRS)는 거버넌스 변경을 알리는 8-K 보고서를 제출했습니다. 2025년 8월 4일 이사회는 14명에서 15명으로 확대되었으며, David Simmons를 독립 이사로 즉시 임명했습니다. 그의 초기 임기는 2025년 연례 주주총회까지입니다. 이사회는 아직 그를 어떤 위원회에도 배정하지 않았으며, 위원회 배정이 완료되는 대로 수정된 8-K 보고서를 제출할 예정입니다.

Simmons 씨는 Viatris의 다른 비직원 이사들에게 제공되는 표준 현금 및 주식 보상을 받으며, 회사는 그와 관례적인 면책 계약(2020년 10-K 보고서의 부속서 10.25로 이전 제출된 양식)을 체결했습니다. 경영진은 규정 S-K의 항목 404(a)에 따라 공개가 필요한 관련 당사자 거래나 합의가 없다고 밝혔습니다.

2025년 8월 5일자 임명 발표 보도자료는 항목 7.01 아래 부속서 99.1로 제공되며, 법적 책임 목적상 제출된 것으로 간주되지 않습니다. 이 보고서에는 재무제표가 첨부되어 있지 않습니다.

Viatris Inc. (NASDAQ : VTRS) a déposé un formulaire 8-K annonçant un changement de gouvernance. Le 4 août 2025, le conseil d'administration est passé de 14 à 15 membres et a nommé David Simmons en tant qu'administrateur indépendant, avec effet immédiat. Son mandat initial court jusqu'à l'assemblée générale annuelle des actionnaires de 2025. Le conseil ne l'a pas encore affecté à des comités ; un formulaire 8-K modifié sera déposé une fois ces nominations finalisées.

M. Simmons recevra la rémunération habituelle en espèces et en actions versée aux autres administrateurs non salariés de Viatris, et la société a conclu avec lui son accord d'indemnisation habituel (formulaire précédemment déposé en annexe 10.25 au formulaire 10-K de 2020). La direction déclare qu'il n'existe aucun accord ou transaction avec des parties liées nécessitant une divulgation selon l'Item 404(a) du règlement S-K.

Un communiqué de presse daté du 5 août 2025 annonçant la nomination est fourni en tant que Pièce 99.1 sous l'Item 7.01 et est expressément considéré comme non déposé aux fins de responsabilité. Aucun état financier n'accompagne ce rapport.

Viatris Inc. (NASDAQ: VTRS) hat ein 8-K Formular eingereicht, das eine Änderung in der Unternehmensführung ankündigt. Am 4. August 2025 wurde der Vorstand von 14 auf 15 Mitglieder erweitert und David Simmons als unabhängiges Vorstandsmitglied mit sofortiger Wirkung ernannt. Seine erste Amtszeit läuft bis zur Hauptversammlung 2025. Der Vorstand hat ihn noch keinen Ausschüssen zugewiesen; ein geändertes 8-K wird eingereicht, sobald diese Ausschusszuweisungen abgeschlossen sind.

Herr Simmons erhält die übliche Bar- und Aktienvergütung, die auch den anderen nicht angestellten Direktoren von Viatris gewährt wird, und das Unternehmen hat mit ihm die übliche Entschädigungsvereinbarung abgeschlossen (Formular zuvor als Anlage 10.25 zum 2020er 10-K eingereicht). Das Management erklärt, dass keine Vereinbarungen oder Transaktionen mit nahestehenden Personen vorliegen, die gemäß Punkt 404(a) der Regulation S-K offenzulegen wären.

Eine Pressemitteilung vom 5. August 2025, die die Ernennung ankündigt, wird als Anlage 99.1 unter Punkt 7.01 bereitgestellt und gilt ausdrücklich nicht als eingereicht im Hinblick auf Haftungszwecke. Dem Bericht sind keine Finanzberichte beigefügt.

false 0001829802 0001829802 2025-08-05 2025-08-05
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

 

 

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39980   83-1863385

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1405 Research Blvd, Suite 125

Rockville, MD

  20850
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

 

Trading

symbol

 

Name of each exchange

on which registered

Common Stock   SNSE   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 
 


Item 2.02

Results of Operations and Financial Condition.

On August 5, 2025, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number

  

Exhibit Description

99.1    Press Release of Sensei Biotherapeutics, Inc., dated August 5, 2025
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Sensei Biotherapeutics, Inc.
Date: August 5, 2025      

/s/ Christopher W. Gerry

      Christopher W. Gerry
      General Counsel and Secretary

 

3

FAQ

Who was appointed to Viatris (VTRS) board of directors?

David Simmons was appointed as an independent director effective 4 Aug 2025.

How many directors does Viatris have after the appointment?

The board size increased from 14 to 15 directors.

When does David Simmons’ term on the Viatris board expire?

His term runs until the company’s 2025 annual meeting of shareholders.

Have committee assignments been decided for the new director?

No. The board will determine committee placements later and file an amended 8-K once finalized.

Does the 8-K include any financial statements or earnings data?

No, the filing contains no financial statements; it is limited to governance matters.

Is the accompanying press release considered filed under the Exchange Act?

No. The press release in Exhibit 99.1 is furnished under Item 7.01 and explicitly not deemed “filed.”
Sensei Biotherapeutics, Inc.

NASDAQ:SNSE

SNSE Rankings

SNSE Latest News

SNSE Latest SEC Filings

SNSE Stock Data

13.01M
829.83k
34.16%
7.69%
0.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE